|
Volumn 30, Issue 11, 2003, Pages 1571-1573
|
Against
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CIPROFLOXACIN;
CIPROFLOXACIN TC 99M;
FLUORODEOXYGLUCOSE F 18;
GALLIUM CITRATE GA 67;
HUMAN IMMUNOGLOBULIN;
HUMAN IMMUNOGLOBULIN TC 99M;
INTERLEUKIN 2;
INTERLEUKIN 2 TC 99M;
INTERLEUKIN 8;
INTERLEUKIN 8 TC 99M;
LEUKOCYTE IN 111;
LEUKOCYTE TC 99M;
RADIOPHARMACEUTICAL AGENT;
TECHNETIUM 99M;
UNCLASSIFIED DRUG;
DIAGNOSTIC AGENT;
COST EFFECTIVENESS ANALYSIS;
DIABETES MELLITUS;
DIAGNOSTIC ACCURACY;
EVIDENCE BASED MEDICINE;
GLUCOSE METABOLISM;
HUMAN;
INFECTION;
INFLAMMATORY DISEASE;
INTERMETHOD COMPARISON;
METABOLIC DISORDER;
POSITRON EMISSION TOMOGRAPHY;
RADIODIAGNOSIS;
REVIEW;
SENSITIVITY AND SPECIFICITY;
COMPUTER ASSISTED EMISSION TOMOGRAPHY;
DIFFERENTIAL DIAGNOSIS;
INFLAMMATION;
METHODOLOGY;
NOTE;
PYREXIA IDIOPATHICA;
REPRODUCIBILITY;
RISK ASSESSMENT;
SCINTISCANNING;
DIAGNOSIS, DIFFERENTIAL;
FEVER OF UNKNOWN ORIGIN;
FLUORODEOXYGLUCOSE F18;
HUMANS;
INFECTION;
INFLAMMATION;
RADIOPHARMACEUTICALS;
REPRODUCIBILITY OF RESULTS;
RISK ASSESSMENT;
SENSITIVITY AND SPECIFICITY;
TOMOGRAPHY, EMISSION-COMPUTED;
|
EID: 0242355149
PISSN: 16197070
EISSN: None
Source Type: Journal
DOI: 10.1007/s00259-003-1360-5 Document Type: Review |
Times cited : (17)
|
References (10)
|